Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BLS Pharmaceuticals's enterprise value is A$220.84 Mil.
BLS Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$8.82 Mil. Therefore, BLS Pharmaceuticals's EV-to-EBITDA for today is 25.04.
The historical rank and industry rank for BLS Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
ASX:BLS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -85 Med: -9.76 Max: 53.14
Current: 25.04
During the past 13 years, the highest EV-to-EBITDA of BLS Pharmaceuticals was 53.14. The lowest was -85.00. And the median was -9.76.
ASX:BLS's EV-to-EBITDA is ranked worse than 68.51% of 397
companies
in the Biotechnology industry
Industry Median: 12.31
vs ASX:BLS: 25.04
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BLS Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
BLS Pharmaceuticals's share price for today is A$0.97.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BLS Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.037.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for BLS Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BLS Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's EV-to-EBITDA falls into.
BLS Pharmaceuticals's current Enterprise Value is A$220.84 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BLS Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$8.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals (ASX:BLS) has a EV-to-EBITDA of 25.04 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BLS Pharmaceuticals. According to the industry distribution chart, BLS Pharmaceuticals ranks #272 out of 397 companies in the Biotechnology industry, placing it in the top 68.5%.
Is BLS Pharmaceuticals' EV-to-EBITDA too high?
BLS Pharmaceuticals' current EV-to-EBITDA is 25.04. The Biotechnology industry median EV-to-EBITDA is 12.31. BLS Pharmaceuticals' value of 25.04 is 103.4% above this industry median. Based on the distribution chart, BLS Pharmaceuticals ranks #272 out of 397 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BLS Pharmaceuticals has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' EV-to-EBITDA compare to KHC and GIS?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #272 out of 397 companies for EV-to-EBITDA. This places BLS Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 12.31. BLS Pharmaceuticals' value of 25.04 is 103.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.31, based on 397 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLS Pharmaceuticals's current EV-to-EBITDA of 25.04 is 103.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BLS Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 12.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLS Pharmaceuticals's current EV-to-EBITDA is 25.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (ASX:BLS) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.69, compared to a current price of A$0.97 — trading 40.6% above its estimated fair value. The current EV-to-EBITDA is 25.04 and 103.4% above the Biotechnology industry median of 12.31. BLS Pharmaceuticals' overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For BLS Pharmaceuticals (ASX:BLS), the current EV-to-EBITDA is 25.04 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (ASX:BLS) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of A$0.97 is trading 40.6% above its estimated GF Value™ of A$0.69.
GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ASX:BLS:
EV-to-EBITDA: 25.04
GF Value™: A$0.69 vs. price of A$0.97 (40.6% above fair value)
Industry Position: 103.4% above the Biotechnology median (#272 of 397)
No single metric tells the full story. See the ASX:BLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
46GF Score
Get the complete analysis for ASX:BLS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BLS has been successfully added to your 
